Figure 1

Risk of tMDS and tAML after NSCLC by stage and time period of NSCLC diagnosis. CI confidence interval, NSCLC non-small cell lung carcinoma, SIR standardized incidence ratio, tMDS treatment-related myelodysplastic syndrome, tAML treatment-related acute myeloid leukemia. ‘tAML’ and ‘tMDS’ inside the figure represents number of patients diagnosed with t-AML or tMDS, in the respective periods.